This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2012 May 15;184(8):857-8.

doi: 10.1503/cmaj.111710. Epub 2012 Jan 23.

Chronic myeloid leukemia: the race is yet to be won

Affiliations

PMID: 22271914
PMCID: PMC3348186
DOI: 10.1503/cmaj.111710

Chronic myeloid leukemia: the race is yet to be won

Jorge Cortes. CMAJ. 2012.

. 2012 May 15;184(8):857-8.

doi: 10.1503/cmaj.111710. Epub 2012 Jan 23.

Author

Affiliation

¹ University of Texas, MD Anderson Cancer Center, Houston, Tex., USA. jcortes@mdanderson.org

PMID: 22271914
PMCID: PMC3348186
DOI: 10.1503/cmaj.111710

No abstract available

PubMed Disclaimer

Similar articles

Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
White DL. White DL. Leuk Lymphoma. 2008 Jun;49(6):1022-3. doi: 10.1080/10428190802074635. Leuk Lymphoma. 2008. PMID: 18452091 No abstract available.
3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I. Jinnai I. Intern Med. 2007;46(2):95-7. doi: 10.2169/internalmedicine.46.1781. Epub 2007 Jan 15. Intern Med. 2007. PMID: 17220607 Review. No abstract available.
Chronic myeloid leukemia. Sceptical scientists.
Druker BJ. Druker BJ. Lancet. 2001 Dec;358 Suppl:S11. doi: 10.1016/s0140-6736(01)07024-6. Lancet. 2001. PMID: 11784560 No abstract available.
[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
Liu H, Chen XG. Liu H, et al. Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):561-3. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17236546 Review. Chinese. No abstract available.
Two new agents effective in Gleevec-resistant CML.
[No authors listed] [No authors listed] Cancer Biol Ther. 2004 Dec;3(12):1198-9. Cancer Biol Ther. 2004. PMID: 15864854 No abstract available.

See all similar articles

References

1. Lee H, Cortes JE, O’Brien S, et al. Improved survival in chronic myeloid leukemia (CML) since the introduction of imatinib therapy: a single institution historital experience [abstract]. Blood 2001;2750. - PMC - PubMed
1. Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) 2009;114:1126
1. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141–5 - PMC - PubMed
1. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232–40 - PMC - PubMed
1. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251–9 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information